Medeon Biodesign, Inc. (TPEX:6499)

Taiwan · Delayed Price · Currency is TWD

91.30

-1.70 (-1.83%)

At close: Feb 26, 2026

109.40% (1Y)

Market Cap	8.42B
Revenue (ttm)	381.90M
Net Income (ttm)	-739.79M
Shares Out	92.24M
EPS (ttm)	-8.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	955,387
Average Volume	729,409
Open	93.00
Previous Close	93.00
Day's Range	91.20 - 94.30
52-Week Range	34.75 - 154.50
Beta	0.87
RSI	43.62
Earnings Date	Feb 11, 2026

About Medeon Biodesign

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to pr... [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 2012

Employees 39

Stock Exchange Taipei Exchange

Ticker Symbol 6499

Full Company Profile

Financial Performance

In 2024, Medeon Biodesign's revenue was 292.81 million, an increase of 49.19% compared to the previous year's 196.26 million. Losses were -805.51 million, -33.13% less than in 2023.

Financial Statements

News

There is no news available yet.